Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Air pollution: outdoor air quality and health

June 2017: NICE Public Health Guidance

British Association of Dermatologists' guidelines for biologic interventions for psoriasis (update)

July 2017: Independent professional body guideline

Psoriasis (Primary Care Dermatology Society)

July 2017: Independent professional body guideline

Cardiac rehabilitation (update)

July 2017: SIGN guidance

Chronic kidney disease (QS update)

July 2017: NICE Quality Standard

Low back pain and sciatica in over 16s

July 2017: NICE Quality Standard

CVD prevention (update)

July 2017: SIGN guidance

Developmental follow-up of children and young people born preterm

August 2017: NICE Clinical Guideline

HIV testing

August 2017: NICE Quality Standard

Rehabilitation after critical illness

August 2017: NICE Quality Standard

Visit the Guidelines website

NICE says OK to Opdivo for lung cancer via CDF

NICE says OK to Opdivo for lung cancer via CDF 20 Sep 2017

BMS’s PD-1 inhibitor will be available as a second-line therapy for NSCLC patients

NICE: We're the institute of 'yes'

NICE: We're the institute of 'yes' 11 Sep 2017

But Meindert Boysen says affordability conversations with pharma need to happen earlier

Takeda can't sway NICE on oral myeloma therapy Ninlaro

Takeda can't sway NICE on oral myeloma therapy Ninlaro 6 Sep 2017

Drug not recommended for NHS use in England and Wales

Dismay as NICE turns down first-line use of AZ's Faslodex

Dismay as NICE turns down first-line use of AZ's Faslodex 4 Sep 2017

Says evidence isn’t convincing for use in post-menopausal women

NICE backs Allergan's IBS therapy Truberzi

NICE backs Allergan's IBS therapy Truberzi 1 Sep 2017

The drug is the only EU licensed IBS-D treatment

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Infographics